We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Recombinant PreS‐fusion protein vaccine for birch pollen and apple allergy.
- Authors
Khaitov, Musa; Shilovskiy, Igor; Valenta, Rudolf; Weber, Milena; Korneev, Artem; Tulaeva, Inna; Gattinger, Pia; van Hage, Marianne; Hofer, Gerhard; Konradsen, Jon R.; Keller, Walter; Akinfenwa, Oluwatoyin; Poroshina, Alina; Ilina, Nataliya; Fedenko, Elena; Elisyutina, Olga; Litovkina, Alla; Smolnikov, Evgenii; Nikonova, Aleksandra; Rybalkin, Sergei
- Abstract
Background: IgE cross‐sensitization to major birch pollen allergen Bet v 1 and pathogenesis‐related (PR10) plant food allergens is responsible for the pollen‐food allergy syndrome. Methods: We designed a recombinant protein, AB‐PreS, consisting of non‐allergenic peptides derived from the IgE‐binding sites of Bet v 1 and the cross‐reactive apple allergen, Mal d 1, fused to the PreS domain of HBV surface protein as immunological carrier. AB‐PreS was expressed in E. coli and purified by chromatography. The allergenic and inflammatory activity of AB‐PreS was tested using basophils and PBMCs from birch pollen allergic patients. The ability of antibodies induced by immunization of rabbits with AB‐PreS and birch pollen extract‐based vaccines to inhibit allergic patients IgE binding to Bet v 1 and Mal d 1 was assessed by ELISA. Results: IgE‐binding experiments and basophil activation test revealed the hypoallergenic nature of AB‐PreS. AB‐PreS induced lower T‐cell activation and inflammatory cytokine production in cultured PBMCs from allergic patients. IgG antibodies induced by five injections with AB‐PreS inhibited allergic patients' IgE binding to Bet v 1 and Mal d 1 better than did IgG induced by up to 30 injections of six licensed birch pollen allergen extract‐based vaccines. Additionally, immunization with AB‐PreS induced HBV‐specific antibodies potentially protecting from infection with HBV. Conclusion: The recombinant AB‐PreS‐based vaccine is hypoallergenic and superior over currently registered allergen extract‐based vaccines regarding the induction of blocking antibodies to Bet v 1 and Mal d 1 in animals.
- Subjects
IMMUNOGLOBULIN E; ALLERGIC rhinitis; BIRCH; MILK allergy; RECOMBINANT proteins; ESCHERICHIA coli; ALLERGIC conjunctivitis; CARRIER proteins
- Publication
Allergy, 2024, Vol 79, Issue 4, p1001
- ISSN
0105-4538
- Publication type
Article
- DOI
10.1111/all.15919